Business
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028 WA
About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
[{"type":"image","alt":"Crescent Biopharma, Inc.","displaySize":"","headline":null,"caption":"Crescent Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/26e5f5c519800f1bba8b99da2f3df5ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G8cbRsK80RDbmmGQ5j.tlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/26e5f5c519800f1bba8b99da2f3df5ab","width":300,"height":107}},"lazy":false},{"type":"text","content":"Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs","length":163,"tagName":"p"},{"type":"text","content":"ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 ","length":179,"tagName":"p"},{"type":"text","content":"Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028","length":153,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.","length":366,"tagName":"p"},{"type":"text","content":"“2025 was a transformational year for Crescent and our efforts to deliver next generation therapies that can improve outcomes for people living with cancer. We expanded our pipeline and accelerated our efforts to deliver best-in-class novel combinations through our exciting partnership with Kelun-Biotech,” said Joshua Brumm, chief executive officer of Crescent. “We now have our Phase 1/2 ASCEND clinical trial underway for CR-001, which is positioned to be an immuno-oncology backbone in the treatment of solid tumors. Three more trials are on track to initiate this year, including the first Phase 1/2 ADC combination trial with CR-001. We are rapidly advancing toward multiple clinical data readouts beginning in the first quarter of 2027 ...
More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H